Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

Better Survival in Refractory CRC With Chemo Plus Bevacizumab, Real-World Study Says



(MedPage Today) — Overall survival (OS) in refractory metastatic colorectal cancer (mCRC) improved significantly with the addition of the VEGF inhibitor bevacizumab (Avastin) to chemotherapy, data from a real-world analysis showed.
A propensity…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments